NET Patient Foundation Research Abstracts
NPF and NCRAS Public Health England partnership project has been compiling statistics on the incidence, prevalence and survival of NET patients in England using English cancer registry data, with an aim to also access Scottish, Welsh and Northern Irish cancer registry data to also get UK wide statistics.
We carried out four pieces of research in 2017, abstracts for which can be found below:
- The Incidence and Prevalence of Neuroendocrine Tumours in England.
- The 1- year survival rates for Neuroendocrine tumour patients in England.
- Metachronus primary cancers in Neuroendocrine tumour patients.
- Neuroendocrine Tumour patients experiences of support in the community setting across the treatment trajectory.
Presenting symptoms and delay in diagnosis of gastrointestinal and pancreatic Neuroendocrine tumours
Ileocolonic neuroendocrine tumours identified in the English bowel cancer screening programme
Self-reported side effects in neuroendocrine tumour (NET) patients prescribed somatostatin analogues – the role for specialist dietitians and nurses
- Assess what symptoms/side effects patients report on SSA’s.
- Assess the severity of symptoms/side effects reported by patients whilst on SSA’s.
- Produce recommendations on how to deal with symptoms commonly experienced by patients on SSA’s.
This study has been accepted to be published in the British Journal of Nursing.
Recent News
Winter Vaccinations & Staying Well This Season
Winter Vaccinations & Staying Well This Season As the colder months roll in, many of our community are doing what they can to keep well through winter – including protecting themselves and loved ones by getting vaccinated against certain winter illnesses, like...
Bronchopulmonary Carcinoids (BPCs) Unveiled – In-Person Event – 12th January 2026
Save the Date: Monday, January 12, 2026 — Bridging the Gaps in Care and Shaping the Future is a high-quality, in-person national educational event taking place from 8:30 AM to 4:30 PM at the Holiday Inn Manchester – City Centre. Aimed at all clinicians involved in the care of patients with BPCs, the day will provide up-to-date insights on diagnosis, treatment, and long-term management, while highlighting unmet needs and setting future priorities for improving care. This event also offers a unique opportunity for UK-wide networking and collaboration.
Catherine Bouvier Ellis steps down after 19 years leading Neuroendocrine Cancer UK
Neuroendocrine Cancer UK today announces that Catherine Bouvier Ellis, its Co-Founder and Chief Executive Officer, will be stepping down from her role on October 8, 2025, after two decades of transformative leadership and unwavering dedication to the neuroendocrine...